Table 4.
Variation of active pharmaceutical ingredient (API) prices to make antiretroviral (ARV) formulations, comparing the years 2005, 2010 and 2015 from various sources including the World Health Organization (WHO) [8,26].
| API price for different ARVs of generic companies |
WHO price in 2005
(US$) |
WHO price in 2010 (US$) |
Reduction of the price from 2005 to 2010 (%) |
HO price in 2015
(US$) |
Reduction of the price from 2010 to 2015 (%) |
2015 generic producers' prices on the market (US$) |
Reduction of the price (%) |
|---|---|---|---|---|---|---|---|
| Atazanavir | NA | 1400 | - | 1000 | 29 | 921 | 8 |
| Darunavir | NA | NA | - | 1500 | - | 922 | 38 |
| Efavirenz | 1200 | 250 | 79 | 120 | 52 | 105 | 13 |
| Emtricitabine | NA | 320 | 0 | 280 | 13 | 231 | 18 |
| Lamivudine | 295 | 160 | 46 | 120 | 25 | 174 | - |
| Tenofovir | 3000 | 500 | 83 | 180 | 64 | 187 | - |
| Ritonavir | 2600 | 900 | 65 | 622 | 31 | 911 | - |
| Lopinavir | 2900 | 1150 | 60 | 408 | 65 | 526 | - |
| Nevirapine | 320 | 156 | 51 | 110 | 29 | 102 | 7 |
| Zidovudine | 360 | 260 | 36 | 230 | 12 | 186 | 19 |
| Dolutegravir | NA | NA | - | 5000 | - | NA | - |
| Raltegravir | NA | NA | - | NA | - | 3486* | - |
NA = not applicable.